Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · N16837/S040

Artegraft Collagen Vascular Graft

LeMaitre Vascular, Inc. · Decision date Oct 15, 2026

MEDTECHLEDGER EXPLANATIONN16837/S040

What did the FDA decide?

The FDA record for Artegraft Collagen Vascular Graft, PMA N16837/S040, is a 30-day notice under supplement reason "Process Change - Manufacturer/Sterilizer/Packager/Supplier." The listed change is an additional service supplier to perform routine bioburden testing on the graft. The device category is a tissue graft of 6mm and greater, specialty Cardiovascular, product code LXA, applicant LeMaitre Vascular, Inc. The decision is OK30, dated 2026-10-15.

The identifier ties this to the original PMA N16837 only through the shared PMA number; the record does not describe that original approval's scope or its manufacturing chain. It is a manufacturing notice, not a new approval of the whole system. The statement's reported purpose is bioburden testing by an added supplier; it is not independent evidence of safety or clinical effectiveness. Absent are the supplier's identity, testing methods, site details, and acceptance criteria.

FDA approval order statement

an additional service supplier to perform routine bioburden testing on the Artegraft Collagen Vascular Graft
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Oct 15, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
N16837/S040
Regulatory pathway
PMA supplement
Product code
LXA
Decision code
OK30
Decision date
Oct 15, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Tissue graft of 6mm and greater.

Product code
LXA
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. N16837/S040 received

    Application receipt date recorded by FDA.

  2. N16837/S040 · FDA decision

    30-Day Notice

Related devices and submissions

Explore the linked device profile

Other records with product code LXA

Product / regulatory recordCompanyPathwayDecision dateSource
LeMaitre Vascular, Inc.PMA supplementSep 4, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

LeMaitre Vascular, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
63 Second Ave., Burlington, MA, 01803

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records